[go: up one dir, main page]

AR010995A1 - Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal. - Google Patents

Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal.

Info

Publication number
AR010995A1
AR010995A1 ARP970104497A ARP970104497A AR010995A1 AR 010995 A1 AR010995 A1 AR 010995A1 AR P970104497 A ARP970104497 A AR P970104497A AR P970104497 A ARP970104497 A AR P970104497A AR 010995 A1 AR010995 A1 AR 010995A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulations
administrable
via nasal
esters
salts
Prior art date
Application number
ARP970104497A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9716805.8A external-priority patent/GB9716805D0/en
Priority claimed from GBGB9719203.3A external-priority patent/GB9719203D0/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of AR010995A1 publication Critical patent/AR010995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se propone el uso de la mupirocina, sales o ésteres de la misma, para tratar infecciones bacterianas asociadas con la colonizacion nasofaríngea talcomo la sinusitis y la otitis recurrente, en particular con nuevas formulaciones enforma de pulverizadores o crema destinadas para seradministradas via nasofaríngea.
ARP970104497A 1996-10-01 1997-09-30 Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal. AR010995A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2722296P 1996-10-01 1996-10-01
US2722396P 1996-10-01 1996-10-01
US2722496P 1996-10-01 1996-10-01
GBGB9716805.8A GB9716805D0 (en) 1997-08-09 1997-08-09 Novel composition and use
GBGB9719203.3A GB9719203D0 (en) 1997-09-11 1997-09-11 Novel composition and use

Publications (1)

Publication Number Publication Date
AR010995A1 true AR010995A1 (es) 2000-08-02

Family

ID=27517419

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104497A AR010995A1 (es) 1996-10-01 1997-09-30 Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal.

Country Status (17)

Country Link
US (1) US6001870A (es)
EP (1) EP0939631A1 (es)
JP (1) JP2001504091A (es)
KR (1) KR20000048812A (es)
CN (1) CN1239427A (es)
AR (1) AR010995A1 (es)
AU (1) AU724070B2 (es)
BR (1) BR9711843A (es)
CA (1) CA2267248A1 (es)
CZ (1) CZ112499A3 (es)
HU (1) HUP9904308A3 (es)
IL (1) IL129237A0 (es)
NO (1) NO991548L (es)
NZ (1) NZ334913A (es)
PL (1) PL332642A1 (es)
TR (1) TR199900733T2 (es)
WO (1) WO1998014189A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939631A1 (en) * 1996-10-01 1999-09-08 Smithkline Beecham Corporation Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms
CO4910145A1 (es) 1996-10-01 2000-04-24 Smithkline Beecham Corp Uso
CA2299298A1 (en) * 1997-08-09 1999-02-18 Jane Elizabeth Hilton Compositions for nasal administration
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9902138D0 (en) 1999-02-02 1999-03-24 Smithkline Beecham Container
TR200102234T2 (tr) * 1999-02-03 2002-10-21 Biogal Gyogyszergyar Rt. Psödomonik asit A antibiyotiğinin mikrobiyolojik yöntem ile hazırlanması için işlem
AU5397300A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
CA2448547A1 (en) * 2001-06-21 2003-01-03 Biogal Gyogyszergyar Rt. Metabolic controlled fermentation process for pseudomonic acid production
KR20040075857A (ko) * 2001-12-28 2004-08-30 비오갈 기오기스제르갸르 알티. 결정질 및 비결정질 무피로신 칼슘의 제조 방법
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005117837A1 (en) * 2004-06-01 2005-12-15 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of amorphous form of a drug
CN101137359B (zh) * 2005-03-10 2011-01-12 3M创新有限公司 治疗耳感染的方法
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
AU2006223136A1 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
JP2011524367A (ja) 2008-06-12 2011-09-01 メドトロニック・ゾーメド・インコーポレーテッド 慢性の創傷を治療するための方法
US20100021563A1 (en) * 2008-07-24 2010-01-28 Paul Levesque Compositions comprising coconut oil and methods of use thereof
US20100086576A1 (en) 2008-10-06 2010-04-08 Myntti Matthew F Antimicrobial composition and methods of making and using same
JP6463629B2 (ja) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ 抗菌性固体およびその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200918A (en) * 1981-07-02 1985-07-31 Gist Brocades Nv Stable fatty oil-in-water emulsion cream for topical application
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
SE8206744D0 (sv) * 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
GB8530796D0 (en) * 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
US5594026A (en) * 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
JPH09506865A (ja) * 1993-10-22 1997-07-08 スミスクライン・ビーチャム・コーポレイション 新規組成物
EP0939631A1 (en) * 1996-10-01 1999-09-08 Smithkline Beecham Corporation Use of mupirocin for the manufacture of a medicament for the treatment of bacterial infections associated with colonisation of the nasopharynx by pathogenic organisms

Also Published As

Publication number Publication date
PL332642A1 (en) 1999-09-27
KR20000048812A (ko) 2000-07-25
AU4562397A (en) 1998-04-24
EP0939631A1 (en) 1999-09-08
HUP9904308A2 (hu) 2001-04-28
NZ334913A (en) 2001-03-30
NO991548D0 (no) 1999-03-30
WO1998014189A1 (en) 1998-04-09
NO991548L (no) 1999-03-31
US6001870A (en) 1999-12-14
TR199900733T2 (xx) 1999-07-21
BR9711843A (pt) 2001-07-31
IL129237A0 (en) 2000-02-17
AU724070B2 (en) 2000-09-14
HUP9904308A3 (en) 2002-06-28
JP2001504091A (ja) 2001-03-27
CZ112499A3 (cs) 1999-08-11
CA2267248A1 (en) 1998-04-09
CN1239427A (zh) 1999-12-22

Similar Documents

Publication Publication Date Title
AR010995A1 (es) Uso de la mupirocina, sales o esteres de la misma en la obtencion de medicamentos administrables via nasal y formulaciones farmaceuticas inclusiveformulaciones farmaceuticas administrables via nasal.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
ES2171158T3 (es) Derivados de oxatiolano cristalizados.
DE69231522D1 (de) 1-substituierte-4-amino-1h-imidazo 4,5-c chinoline, zwischenprodukte und arzneimittel
MX9202066A (es) Composiciones a base de acido graso para el control de infecciones establecidas en plantas.
ES2233931T3 (es) Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
ES2179040T3 (es) Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
AR021074A1 (es) COMPOSICIoN FARMACÉUTICA DE MOXIFLOXACINA, PROCEDIMIENTO PARA SU PRODUCCIoN, Y USO DE DICHA COMPOSICIoN PARA PREPARAR UN MEDICAMENTO ANTIBACTERIANO.
ITRM930399A0 (it) Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
ITMI921930A1 (it) Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
TR199900661T2 (xx) Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m�
FI960850A0 (fi) Kinoksaliinien käyttö proteaasi-inhibiittoreihin yhdistettyinä lääkkeeksi AIDS:in ja/tai HIV-tartuntojen hoitamiseksi
ITRM930365A0 (it) Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IT8619284A0 (it) Composizione per la preparazione estemporanea di formulazioni per applicazioni topiche per uso farmaceutico e cosmetico.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ES2092559T3 (es) Formulacion farmaceutica que contiene penciclovir.
EP0302836A1 (en) Pharmaceutical compositions for topical use containing miocamycin
ES2128353T3 (es) Composicion topica que contiene penciclovir.
ES2032476T3 (es) Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina.
PT1232173E (pt) Derivados do acido fusidico
PT1208078E (pt) Sais nao higroscopicos de substancias activas com actividades terapeuticas e/ou nutricionais e composicoes passiveis de serem administradas oralmente contendo os mesmos
CO4790092A1 (es) Granisetron para tratamiento de la diarrea
ITRM920930A0 (it) Impiego del glutatione per la preparazione di composizioni farmaceutiche ad attivita' antivirale.